How to Future-Proof Your Company with Smarter IT Choices 
BOSS Zhipin Continues Share Repurchases: More than RMB340M in 2026 Under Buyback Program Trivest Announces Promotions Across the Firm
MIAMI–(BUSINESS WIRE)–Trivest Partners (“Trivest” or the “Firm”) is pleased to announce the following promotions —…
Hildred Capital Management, LLC, Bourne Partners Strategic Capital and The Emerson Group Launch Carlin Consumer Health
Acquires ZEGERID OTC® for Heartburn Treatment from Bayer Well-Capitalized OTC Platform to Acquire and Grow…
defi SOLUTIONS Business Process Outsourcing (BPO) Implements State-of-the-Art Technology: Amazon Lex, chatbots with conversational AI, and Genesys®, a global cloud leader in customer experience orchestration
Working remotely or in-facility, defi team members offer digital, AI-enabled experience to lenders and their…
Migdal Insurance Commits to Invest in Doral Renewables’ Mammoth South Project
Migdal Insurance, Israel’s leading insurance company, has committed to invest up to $75 million into…
Surfaceink Launches Innovation Lab for Consumer Electronic Product Development
SAN JOSE, Calif.–(BUSINESS WIRE)–#IoT–Surfaceink, a pioneering Silicon Valley Product Development company, announced the launch of…
PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceuticals Development
Sandusky, OH, Feb. 01, 2022 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) today…
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 Immix Biopharma,…
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE)…
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
CHENGDU, China, Feb. 01, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a…
Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI),…
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable…
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a…
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
Quotient Limited Provides MosaiQ Regulatory & Commercial Update
The company remains in contact with the European Notified Body and continues to anticipate approval…
POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs
Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial –…
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path…
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
— Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected…
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”…
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…